Skip to content
Altius – Lifestyle
Author:
Nasus Pharma, Ltd.
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
March 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
March 9, 2026
←
Previous Page
1
2